Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

NCT06132035 ↗

Phase 1 Recruiting 45 enrolled Caregen Co. Ltd. CBCC Global Research · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This will be a randomized, comparative, parallel, clinical study to assess initial safety and tolerability of CG-P5 peptide eye drops compared to placebo in patients diagnosed with age-related wet macular degeneration

Timeline

Start: 2023-12-22
Primary completion: 2025-05
Completion: 2025-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Aflibercept	Protein / enzyme biologic	—	Intravitreal
Subject	CG-P5	Peptide	—	Topical

Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

Summary

Timeline

Drugs

Indications